Trial Profile
Phase 1a single ascending dose study of CNM-Au8 in healthy human volunteers
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 10 May 2016
Price :
$35
*
At a glance
- Drugs CNM Au8 (Primary)
- Indications Demyelinating disorders
- Focus Adverse reactions
- 10 May 2016 According to Clene Nanomedicine website, the US FDA has granted approval to proceed with this study.
- 10 May 2016 New trial record